Personal Investment Vitae

Home > Personal Investment Vitae

AYA Personal Investment Vitae as of March 2026
Rose Prince @Rose Prince
Platinum member since January 2017

Location: United States

Gender: Female

Asset investment style: Quantitative technical analysis

Market capitalization:

$7,433,223talents

Virtual portfolio value:

$4,448,732talents

Net overall return per annum:

17.53%

AYA current rank order:

#12

Asset investment philosophy:
Rose Prince trades U.S. stocks with the top #201 to #500 positive alpha signals.

Top 10 profitable stock transactions since January 2020Strategy

Symbol Company Buy Sell Share Volume Return (%) Profit ($)
VATE INNOVATE Corp. Common Stock $0.53 $4.14 91,603 +681.13% $330,687
RMBL RumbleOn Inc. Class B Common Stock $0.36 $7.95 12,852 +2,108.33% $97,547
LGVN Longeveron Inc. Class A Common Stock $3.45 $26.25 3,340 +660.87% $76,152
LSCC Lattice Semiconductor Corporation Common Stock $6.97 $48.04 1,665 +589.24% $68,382
TUEM Tuesday Morning Corp. Common Stock $0.12 $0.69 103,558 +475.00% $59,028
NTZ Natuzzi S.p.A. $2.21 $11.92 5,254 +439.37% $51,016
GNRC Generac Holdlings Inc. Common Stock $42.64 $219.38 272 +414.49% $48,073
CDNS Cadence Design Systems Inc. Common Stock $29.82 $150.85 389 +405.87% $47,081
MPWR Monolithic Power Systems Inc. Common Stock $85.91 $392.24 135 +356.57% $41,355
BBX BBX Capital Corporation $2.54 $14.54 2,191 +472.44% $26,292
Sum $845,613

Top 10 current stock portfolio positions as of March 2026Strategy

Top 20 influencers

#1 - #5 #6 - #10 #11 - #15 #15 - #20
@alin
@Andy Yeh Alpha

Blog+More

Top money managers George Soros and Warren Buffett reveal their current stock and bond positions.

Dan Rochefort

2018-05-10 07:37:00 Thursday ET

Top money managers George Soros and Warren Buffett reveal their current stock and bond positions.

Top money managers George Soros and Warren Buffett reveal their current stock and bond positions in their recent corporate disclosures as of mid-2018. Georg

+See More

Our fun podcasts deep-dive into the current global trends, topics, and issues in support of better stock market investment decisions.

Daphne Basel

2026-02-14 11:26:00 Saturday ET

Our fun podcasts deep-dive into the current global trends, topics, and issues in support of better stock market investment decisions.

Our AYA fun podcasts deep-dive into the current global trends, topics, and issues in macro finance, political economy, public policy, strategic management,

+See More

We can decipher valuable lessons from the annual letters to shareholders written by Amazon CEO Jeff Bezos.

Becky Berkman

2019-07-19 18:40:00 Friday ET

We can decipher valuable lessons from the annual letters to shareholders written by Amazon CEO Jeff Bezos.

We can decipher valuable lessons from the annual letters to shareholders written by Amazon CEO Jeff Bezos. Amazon is highly customer-centric because the wor

+See More

American state attorneys general begin bipartisan antitrust investigations into Apple, Amazon, Facebook, and Google.

Charlene Vos

2019-10-21 10:35:00 Monday ET

American state attorneys general begin bipartisan antitrust investigations into Apple, Amazon, Facebook, and Google.

American state attorneys general begin bipartisan antitrust investigations into the market power and corporate behavior of central tech titans such as Apple

+See More

The Trump administration expects to reach an interim partial trade deal with China.

Jacob Miramar

2019-11-05 07:41:00 Tuesday ET

The Trump administration expects to reach an interim partial trade deal with China.

The Trump administration expects to reach an interim partial trade deal with China. This interim partial trade deal represents the first phase of a comprehe

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More